Fact CheckerSign in

NCT02248519Completed

Laparoscopic Versus Open Gastrectomy for Gastric Cancer

Laparoscopic Versus Open Gastrectomy for Gastric Cancer, a Multicenter Prospectively Randomized Controlled Trial (LOGICA-trial)

Source: ClinicalTrials.gov · Last updated 19 Feb 2026

Brief summary (registry, in English)

This is the first randomized controlled trial comparing laparoscopic and open gastrectomy for resectable gastric cancer in a Western population. The hypothesis is that laparoscopic gastrectomy will result in a lower post-operative burden by means of shorter post-operative hospital stay. Secondarily that laparoscopic gastrectomy is hypothesized to be associated with lower post-operative morbidity and readmissions, higher cost-effectiveness, and better post-operative quality of life, with similar mortality and oncologic outcomes, compared to open gastrectomy. The study starts on 1 December 2014. Inclusion and follow-up will take three and five years respectively. Short-term results will be analyzed and published after discharge of the last randomized patient.

Status (registry)
Completed
Study type
Interventional
Enrollment
210 (actual)
First submitted
17 Sept 2014
Start date
1 Dec 2014
Primary completion date
1 Nov 2018
Lead sponsor
UMC Utrecht
NCT number
NCT02248519

What you commit to

  • Study type: Interventional
  • Participants enrolled: 210
  • From 1 Dec 2014 to the primary completion date, 1 Nov 2018
  • 10 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Non-elective surgery
  • Previous gastric resection or recurrent gastric cancer

Other

  • Siewert type I esophagogastric junction tumor
  • Pregnancy

Who the study is looking for

  • Histologically proven adenocarcinoma of the stomach
  • Surgically resectable (cT1-4a, N0-3b, M0) tumor
  • Age ≥ 18 years
  • European Clinical Oncology Group (ECOG) performance status 0, 1 or 2.
  • Written informed consent

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (10)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Zorggroep Twente Almelo
Coordinator of this site? Confirm its status
AlmeloNetherlandsUnknown status
Meander Medical Center
Coordinator of this site? Confirm its status
AmersfoortNetherlandsUnknown status
Academic Medical Center
Coordinator of this site? Confirm its status
AmsterdamNetherlandsUnknown status
VU University Medical Center
Coordinator of this site? Confirm its status
AmsterdamNetherlandsUnknown status
Gelre Hospital
Coordinator of this site? Confirm its status
ApeldoornNetherlandsUnknown status
Catharina hospital
Coordinator of this site? Confirm its status
EindhovenNetherlandsUnknown status
Leiden University Medical Center
Coordinator of this site? Confirm its status
LeidenNetherlandsUnknown status
Erasmus Medical Center
Coordinator of this site? Confirm its status
RotterdamNetherlandsUnknown status
Zuyderland Medical Center
Coordinator of this site? Confirm its status
Sittard-GeleenNetherlandsUnknown status
University Medical Center Utrecht
Coordinator of this site? Confirm its status
UtrechtNetherlandsUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.